MARATTO

article · african journal of gastroenterology and hepatology

Significance of the influence of patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 polymorphism on non alcoholic fatty liver disease

20241 citationOpen accessAin Shams University

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by diffuse hepatocyte steatosis. The pathogenesis of NAFLD is not recognized. It has become apparent that genetic, environmental, and metabolic factors drive NAFLD. Moreover, earlier studies have observed that some polymorphisms raise the likelihood of NAFLD. Among these, the most robustly observed was the relationship between NAFLD risk and patatin-like phospholipase domain-containing 3 (PNPLA3). Aim: We aimed to assess the effect of the rs738409 polymorphism of the PNPLA3 gene (encoding I148m) on NAFLD. Patients and Methods: This study, which included 30 participants, was conducted with meticulous attention to detail and thoroughness: 20 patients with NAFLD and ten healthy participants as a control group. Participants were diagnosed according to a liver biopsy taken during surgery from patients who were candidates for bariatric surgery and as part of a predonation assessment for candidates for donation in liver transplantation. Genotyping of the PNPLA3 gene variant (rs738409 C/G) was assessed using the TaqMan assay quantitative polymerase chain reaction in blood cells. Results: Considering the distribution of the PNPLA3 gene variant (rs738409 C/G), a greater prevalence of heterozygous rs738409 CG and homozygous rs738409 GG variants occurred in the NAFLD patients in contrast to the control group (p = 0.048). In addition, NAFLD patients with the homozygous GG variant had a higher incidence of hepatic fibrosis (p = 0.018). Furthermore, PNPLA3 gene polymorphism significantly predicted hepatic steatosis and fibrosis in NAFLD patients (p = 0.033 and p < 0.001, respectively). Conclusion: The PNPLA3 rs738409 polymorphism is significantly associated with the susceptibility and severity of non-alcoholic fatty liver disease.

Research topics

  • Liver Disease Diagnosis and Treatment
  • Diet, Metabolism, and Disease
  • Metabolism, Diabetes, and Cancer

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/ajgh.2024.313440.1061

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.